Aardvark Therapeutics, Inc. AARD 深 沪
等待开盘 09-04 09:30:00 美东时间
8.18
-0.680
-7.67%
华盛通- 最 高9.09
- 今 开9.00
- 成交量 13.30万股
- 最 低 8.10
- 昨 收 8.86
- 总市值 1.77亿
- 52周最高 19.58
- 市盈率 静 --
- 换手率 0.61%
- 52周最低 4.88
- 委 比 -12.36%
- 总股本 2169.59万
- 历史最高 19.58
- 量 比 1.02
- 振 幅 11.17%
- 历史最低 4.88
- 每 手 1
- 风险率 2.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aardvark Therapeutics to Present at Upcoming Investor Conferences in September
Aardvark Therapeutics, a clinical-stage biopharmaceutical company, announced it will present at three conferences in September 2025: the Cantor Fitzgerald Global Healthcare Conference, the Morgan Stanley 23rd Annual Global Healthcare Conference, and the H.C. Wainwright 27th Annual Global Investment Conference, all held in New York. Live webcasts of the presentations are accessible on the company’s website, and archived recordings will be availabl...
08-27 20:10
Aardvark Therapeutics Advances Clinical Trials and Financials
Aardvark Therapeutics, Inc. ( ($AARD) ) has released its Q2 earnings. Here is a...
08-27 12:05
Aardvark Therapeutics Q2 EPS $(0.66) Misses $(0.61) Estimate
Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of $(0.61) by 7.67 percent. This is a 51.82 percent increase over losses of $(1.37) per share
08-14 04:24
Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates
Aardvark Therapeutics reported $141.8 million in cash to support operations into 2027. Key updates include expanding the Phase 3 HERO trial for PWS to include pediatric patients under 13, and advancing ARD-201 into Phase 2 trials focusing on weight management strategies. The company also announced the initiation of the Phase 2 POWER and STRENGTH trials for ARD-201, targeting weight regain prevention and durable weight loss, respectively. Addition...
08-13 20:10
Aardvark Therapeutics Announced Preclinical Data Of ARD-201 For Treatment Of Metabolic Obesity And Obesity-Related Conditions
Globe NewswireIn a gold-standard model of obesity, treatment with ARD-201 resulted in approximately 19% body weight reduction after 30 days of treatment.ARD-201 was also associated with attenuated weight regain after
08-12 20:03
Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy
Aardvark Therapeutics announced positive preclinical data for ARD-201, showing 19% body weight reduction in obese mice and potential to prevent weight regain after GLP-1RA discontinuation. The drug also demonstrated enhanced weight loss when combined with low-dose tirzepatide. Aardvark plans Phase 2 POWER and STRENGTH trials to evaluate ARD-201's efficacy in weight maintenance and as a monotherapy/combination therapy.
08-12 12:00
Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
Aardvark Therapeutics announced that between July 8-14, 2025, two new employees were granted inducement awards consisting of stock options to purchase 10,372 shares of common stock under the 2025 Inducement Equity Incentive Plan. The exercise prices are $13.04 and $12.11, with options vesting over four years. Aardvark is a biopharmaceutical company developing small-molecule therapeutics for metabolic diseases, with its lead compound ARD-101 in Ph...
07-18 12:00
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
07-01 09:24
Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress
Aardvark's lead drug ARD-101 targets PWS and HO with trials underway and funding secured through 2027 after a $94.2 million IPO in February.
07-01 02:06
Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference
Aardvark Therapeutics announced its participation in the 2025 United in Hope Conference, where it will present data from its Phase 2 study of ARD-101 in Prader-Willi Syndrome (PWS) and discuss its ongoing Phase 3 HERO study. The company highlights ARD-101's safety profile and reduced hyperphagia, informing the HERO trial design. Aardvark's team will engage with the PWS community to share insights on ARD-101 and its commitment to addressing PWS.
06-24 12:00
